Accelerating the Development of pan-TB Regimens

Successfully treating TB can be complex and challenging. New regimens with little to no drug resistance – known as pan-TB regimens – create a simpler and more effective treatment pathway for all people diagnosed with TB.

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is the first collaboration of philanthropic, non-profit and private-sector organizations that aims to accelerate the identification of promising pan-TB regimens and conduct research through phase 2b/2c clinical trials. These pan-TB regimens will be designed to have improved safety and tolerability, a shorter duration, and simpler to use than existing treatment options.

New preclinical study data now accessible via the Critical Path Institute

Data from the PAN-TB Collaboration’s 2024 nonclinical studies—covering combination pharmacokinetics, relapsing mouse model (RMM) efficacy, and CFU-R/S ratio mouse model (CRSMM) efficacy—are now available through the Critical Path Institute Data Analytics Platform (CP-DAP).

These studies evaluated the pharmacokinetics and efficacy of novel three– and four-drug combinations of the following priority anti-TB drugs and drug candidates: Bedaquiline (B), Sorfequiline (formerly TBAJ-876), Pretomanid (Pa), Sutezolid (Sut), GSK2556286 (286), GSK3036656 (656), TBD09 (formerly MK-7762), TBD11 (formerly mCLB073), Quabodepistat (Q) (formerly OPC167832 or OPC), Rifapentine (P), Isoniazid (H), Pyrazinamide (P) and Moxifloxacin (M).

Study data available:

Pharmacokinetic assessments of novel four-drug combinations in mice to inform RMM and CRSMM efficacy studies.

RMM evaluations of 12 novel three and four anti-TB drug combinations, assessing bactericidal and sterilizing activity over time, drug pharmacokinetics, and the RS ratio as a pharmacodynamic marker.

CRSMM evaluations of five prioritized four-drug regimens from Wave 2022 and Wave 2023 and corresponding three-drug backbones, where B is replaced by Sorfequiline (formerly TBAJ-876), assessing bactericidal activity, RS ratio trends, and individual drug contributions.

All available data are mapped to the Clinical Data Interchange Standards Consortium (CDISC) Standard for Exchange of Nonclinical Data (SEND). Please note that C-Path has migrated to a new, enhanced platform, which will provide expanded functionality and capabilities for researchers. All available PAN-TB Collaboration data, including earlier 2020-2023 nonclinical studies, are available through the new platform.

Researchers can request access to the data by following the link below. New data will be added as they become available.

Request Access

Overview of Partners

The members of the PAN-TB collaboration have committed to leveraging their unique assets, resources and scientific expertise to advance the development of novel regimens.

PAN-TB Priority Candidates

Bedaquiline

Registered product for multidrug-resistant TB, Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, New Chemical Entity for drug-sensitive TB, TB Alliance